Literature DB >> 20724042

Computational analysis of ligand recognition sites of homo- and heteropentameric 5-HT3 receptors.

Arménio J Moura Barbosa1, Francesca De Rienzo, Maria J Ramos, Maria Cristina Menziani.   

Abstract

Inhibition of the 5-hydroxytryptamine receptor (5-HT(3)R), a member of the Cys-loop superfamily of Ligand-Gated Ion Channels (LGICs), has been recognized to have important antiemetic effects. With respect to the many other drugs already in use, such as the first generation 5-HT(3)R antagonist granisetron, palonosetron, a second generation antagonist, clearly demonstrates superior inhibition potency towards the 5-HT(3)Rs. Five different receptor monomers, the 5-HT(3)R A-E, have been identified although the A and B subunits are the only known to build functional receptors, the homopentameric 5-HT(3A)R and the heteropentameric 5-HT(3B-A)R (with BBABA subunit arrangement). At present, however, no three-dimensional structure has been reported for any of the 5-HT(3)R subunits. To understand the binding properties of agonists and antagonists, models of the extracellular portion of the 5-HT(3)R A and B subunits are built and assembled into the receptor (homo- and hetero-) pentameric structure on the basis of the known three-dimensional structure of the nicotinic-acetylcholine receptor (nACh-R). The results of docking studies of the natural agonist serotonin and the antagonists palonosetron and granisetron into the modelled homomeric and heteromeric 5-HT(3)R binding interfaces, provide a possible rationalization both of the higher potency of palonosetron with respect to other antagonists, and of its previously reported allosteric binding and positive cooperativity properties.
Copyright © 2010 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20724042     DOI: 10.1016/j.ejmech.2010.07.039

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  8 in total

1.  VUF10166, a novel compound with differing activities at 5-HT₃A and 5-HT₃AB receptors.

Authors:  A J Thompson; M H P Verheij; I J P de Esch; S C R Lummis
Journal:  J Pharmacol Exp Ther       Date:  2012-02-03       Impact factor: 4.030

2.  Bivalent Ligands for the Serotonin 5-HT3 Receptor.

Authors:  Andrea Cappelli; Monica Manini; Marco Paolino; Andrea Gallelli; Maurizio Anzini; Laura Mennuni; Marta Del Cadia; Francesca De Rienzo; M Cristina Menziani; Salvatore Vomero
Journal:  ACS Med Chem Lett       Date:  2011-05-09       Impact factor: 4.345

3.  Approaching the 5-HT₃ receptor heterogeneity by computational studies of the transmembrane and intracellular domains.

Authors:  Marta Del Cadia; Francesca De Rienzo; Maria Cristina Menziani
Journal:  J Comput Aided Mol Des       Date:  2013-06-16       Impact factor: 3.686

4.  Agonists and antagonists induce different palonosetron dissociation rates in 5-HT₃A and 5-HT₃AB receptors.

Authors:  Sarah C R Lummis; Andrew J Thompson
Journal:  Neuropharmacology       Date:  2013-06-05       Impact factor: 5.250

5.  Exploring a potential palonosetron allosteric binding site in the 5-HT(3) receptor.

Authors:  Marta Del Cadia; Francesca De Rienzo; David A Weston; Andrew J Thompson; Maria Cristina Menziani; Sarah C R Lummis
Journal:  Bioorg Med Chem       Date:  2013-09-20       Impact factor: 3.641

Review 6.  Discriminating between 5-HT₃A and 5-HT₃AB receptors.

Authors:  A J Thompson; S C R Lummis
Journal:  Br J Pharmacol       Date:  2013-06       Impact factor: 8.739

7.  Prolonged inhibition of 5-HT₃ receptors by palonosetron results from surface receptor inhibition rather than inducing receptor internalization.

Authors:  J Daniel Hothersall; Christopher Moffat; Christopher N Connolly
Journal:  Br J Pharmacol       Date:  2013-07       Impact factor: 8.739

8.  Impact of intracellular domain flexibility upon properties of activated human 5-HT3 receptors.

Authors:  J L Kozuska; I M Paulsen; W J Belfield; I L Martin; D J Cole; A Holt; S M J Dunn
Journal:  Br J Pharmacol       Date:  2014-04       Impact factor: 8.739

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.